Skip to main content
Contact Us
Subscribe
E-Edition
40°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hemogenyx Pharmaceuticals Plc.
(OP:
HOPHF
)
0.0031
UNCHANGED
Last Price
Updated: 12:21 PM EDT, Aug 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Hemogenyx Pharmaceuticals Plc.
< Previous
1
2
Next >
Hemogenyx Pharmaceuticals PLC Announces Ultrafast CAR-T Manufacturing
December 19, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Admission of New Ordinary Shares and New ISIN
December 10, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Site Initiation Visit Completed
December 09, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Macrophage Delivery Update
December 06, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Notice of Extraordinary General Meeting
November 22, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial
November 22, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Institutional Investment
November 10, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
October 02, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CDX Development Update
September 01, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Macrophage-Directed Therapies Summit Presentation
July 28, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Operations Update
June 16, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Half-year Report
September 26, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC - FLT3 Assay Ready for Phase I Trials at MD Anderson
September 08, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Presentation at CBD S&T Conference
August 27, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting
June 27, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Final Results
April 24, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights
March 27, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Brain Delivery
February 15, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Intranasal Delivery
February 13, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T
February 08, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals discusses successful £3.5M capital raise as it advances HEMO-CAR-T program
March 12, 2024
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) Dr Vladislav Sandler joins Proactive's Stephen Gunnion after the pre-clinical stage biopharmaceutical group raised £3.5 million, which will be...
Via
TheNewswire.com
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise US$4.2 million
February 28, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces the Approval and Issuance of U.S. Conditioning Patent
February 01, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Submission of Complete Response to Clinical Hold
January 15, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Process Qualification Run Completed
January 07, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer
November 27, 2023
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Lentivirus Re-manufacturing Completed
November 15, 2023
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
September 18, 2023
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £534,375
November 28, 2023
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC - Clinical Hold Lift Plan is accepted by FDA
September 14, 2023
Via
ACCESSWIRE
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
